US Stock MarketDetailed Quotes

EXAS Exact Sciences

Watchlist

71.930
+2.700+3.90%

Close Oct 18 16:00 ET

72.000
+0.070+0.10%

Post 20:02 ET

13.29BMarket Cap-75715P/E (TTM)

Exact Sciences Stock Forum

103848509

Aug 1 09:47

$Exact Sciences (EXAS.US)$ break 56.9 fly again

knightingale

Jun 14 08:26

$Exact Sciences (EXAS.US)$ guys relax sooner or later this will grow just not so soon

missignite

May 29 12:41

$Exact Sciences (EXAS.US)$ whats happening? why it keeps dropping?

Sikander KHAN

May 9 07:18

Good opportunity to buy more after correction.

$Exact Sciences (EXAS.US)$ Good opportunity to buy after correction, "not today" I shall buy in next week once volatility minimized. Good AI stoks but you can see good return not before 2025. I am bullish on it and it will remain my best pick for next 3-5 years invetment tenure.

Sikander KHAN

Apr 3 15:49

One of the best AI stocks. Still trading at the best price.

Share Your Profit/Loss

Moomoo AI

Mar 15 11:15

Exact Sciences' progress has failed to meet high market expectations, yet its consistent revenue growth suggests it may be worth further investigation. The company's performance has underperformed the broader market, which gained around 31%.

Shareholders in Exact Sciences (NASDAQ:EXAS) Have Lost 54%, as Stock Drops 4.8% This Past Week

Moomoo AI

Feb 23 10:10

The company's strained balance sheet and lack of EBIT level profitability heighten risk. Its debt management and growth rate are key concerns, with faster growth expected from unprofitable firms.

Exact Sciences (NASDAQ:EXAS) Is Making Moderate Use Of Debt

Moomoo AI

Jan 8 11:29

Exact Sciences' low P/S ratio is due to its poor revenue outlook. Investors foresee limited growth, thus are only willing to pay less for the stock, making a strong share price rise unlikely.

Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel

Moomoo AI

Nov 15, 2023 10:35

Exact Sciences' growth rate is somewhat slow, showing a 20% rise in revenue while lacking profitability at an EBIT level. Considerable liabilities and negative EBIT results make its financial status seem precarious and risky.

Is Exact Sciences (NASDAQ:EXAS) A Risky Investment?

Moomoo AI

Oct 25, 2023 11:11

Impressive annual returns suggest the company's improved performance. Its focus on revenue growth proves strategic, although further profitability analysis is wise given the substantial share appreciation.

Exact Sciences (NASDAQ:EXAS) Pulls Back 4.3% This Week, but Still Delivers Shareholders Splendid 104% Return Over 1 Year

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

Concept

Cancer Research

Intraday-0.18%